Lexaria Bioscience Receives Nasdaq Delisting Warning for Sub-$1.00 Bid Price
LEXX sits 58% above its 52-week low of $0.46.
Summary
Lexaria Bioscience Corp. received a Nasdaq deficiency notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period to avoid delisting.
Key Events · Corporate Governance and Compliance · LEXX
-
Nasdaq Bid Price Deficiency Notice
On February 4, 2026, Lexaria Bioscience Corp. received a letter from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.
-
180-Day Compliance Period
The company has 180 calendar days, until August 3, 2026, to regain compliance by having its common stock close at or above $1.00 for at least 10 consecutive business days.
-
Potential for Reverse Stock Split
If compliance is not met within the initial period, the company may be eligible for an additional 180-day period, which could necessitate a reverse stock split to cure the deficiency.
-
Context of Going Concern Warning
This delisting notice follows a recent 10-Q filing on January 13, 2026, where the company expressed substantial doubt about its ability to continue as a going concern, intensifying financial and operational concerns.
Analysis · LEXX · Life Sciences
Lexaria Bioscience Corp. has received a formal notice from Nasdaq regarding its non-compliance with the minimum $1.00 bid price requirement. This is a critical development, especially following the company's recent 10-Q filing on January 13, 2026, which disclosed substantial doubt about its ability to continue as a going concern. The delisting notice adds significant pressure and uncertainty, as maintaining a Nasdaq listing is crucial for investor confidence and liquidity, particularly for a micro-cap company. While the company has 180 days to regain compliance, potentially through a reverse stock split, the underlying financial challenges highlighted by the 'going concern' warning suggest a difficult path ahead. Investors should monitor the company's efforts to address both its financial stability and its Nasdaq listing status.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 42% of the 479 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.44%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEXX was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18M. The 52-week trading range was $0.46 to $1.91. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.